Implementing Seasonal Malaria Chemoprevention in West and Central Africa

Seasonal chemoprevention in children can be provided at scale in malaria-endemic countries, where it reduces malaria illness and deaths.

Administering antimalarial drugs monthly during and immediately after the rainy season (i.e., seasonal malaria chemoprevention [SMC]) reduces malaria burden. Although WHO endorsed this strategy in 2012, SMC was available to only 10% of eligible children by 2014. A project “Achieving Catalytic Expansion of SMC in the Sahel” (ACCESS-SMC) introduced SMC in Burkina Faso, Chad, The Gambia, Guinea, Mali, Niger, and Nigeria. In this observational study, investigators assessed ACCESS-SMC's coverage, safety, effectiveness, association with drug resistance, and cost-effectiveness. Sulfadoxine-pyrimethamine (S-P) plus amodiaquine was administered in 4 monthly doses to children younger than 5 years. Of the 7.5 million children who received treatment in…

Reviewing Authors

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Implementing Seasonal Malaria Chemoprevention in West and Central Africa

Topics

Reviewing Authors